SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this interventional clinical trial is to evaluate the dose of radiation of Technetium-99m macroaggregated-albumin (99mTc-MAA) after an intra-arterial injection to the whole body and non-liver critical organs in patients who are undergoing evaluation for SIR-Spheres treatment for hepatocellular carcinoma.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sirtex Medical
• Collaborator: Bright Research Partners
• Treatments: Technetium Tc 99m Aggregated Albumin

Criteria

Inclusion Criteria:

1. Willing, able, and mentally competent to provide written informed consent

2. Age 18 or older at the time of consent

3. Patients who are being evaluated for SIR-Spheres treatment eligibility

Exclusion Criteria:

1. Patients who are contraindicated for SIR-Spheres treatment

2. Patients who are contraindicated for 99mTc-MAA per the manufacturer's package insert